ClinicalTrials.gg
RecruitingNCT07486843Updated Mar 23, 2026

Preventing Structural Damage in Early Psoriatic Arthritis

A Phase 4 interventional study of Amgevita 40Mg Solution for Injection and Methotrexate (Metoject® prefilled pen) in Psoriatic Arthritis (PsA), sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Chinese University of Hong Kong · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing methotrexate in Arthritis, Psoriatic — 5 open to participants now, 5 under way, 1 of them phase 3. Methotrexate · Arthritis, Psoriatic.

Planned enrollment
6th of 10
108 · median 112
Started
2026
the only one that year
Phase 4
3 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Chinese University of Hong Kong

Among the 10 studies testing methotrexate in Arthritis, Psoriatic, this one is the 6th largest by planned enrollment, is the only one that started in 2026, is one of 3 in phase 4, and was the 10th registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

5 of the 10 studies testing methotrexate in Arthritis, Psoriatic are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing methotrexate in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

Investigators hypothesize that TNFi is superior to SC MTX in preventing structural damage in early, treatment-naïve PsA, assessed using HR-pQCT. The study aims to ascertain:

- The effect of SC MTX and TNFi (adalimumab biosimilar) on erosion and enthesiophyte progression in early PsA by HR-pQCT.

Participants will be:

  • Randomized in a 1:1 ratio to either the SC MTX group or the TNFi group.
  • HR-pQCT of MCPJ 2-4 will be performed at baseline, week 24, and one year.

The primary outcome is the comparison of change in erosion volume over MCPJ 2-4 across 48 weeks between the SC MTX group (group 1) and the TNFi group (group 2), assessed by HR-pQCT.

03

Conditions studied

  • Psoriatic Arthritis (PsA)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years old
  • without severe deformity in MCPJ
  • with active disease, which is defined as ≥1 tender joints and ≥1 swollen joints, despite previous treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) for ≥ 4 weeks
  • with at least one poor prognostic factor (eg, polyarthritis, structural damage on HR-pQCT or CR, elevated acute phase reactants, dactylitis, nail involvement or HAQ-DI>1)
  • symptom duration ≤ 2 years

Exclusion criteria

Exclusion Criteria:

  • on csDMARDs unless being prescribed for skin psoriasis (e.g. cyclosporin)
  • limited in ability to perform usual self-care, vocational, and avocational activities
  • pregnancy
  • previous therapy with b/tsDMARDs
  • predominant active axial PsA or significant uveitis/inflammatory bowel disease requiring immediate b/tsDMARDs therapy
  • the presence of active inflammatory diseases other than PsA
  • active infection in 2 weeks before randomization or a history of ongoing, chronic, or recurrent infections including tuberculosis
  • history of malignant disease within the past 5 years (excluding basal cell carcinoma or actinic keratosis, in-situ cervical cancer, or non-invasive malignant colon polyps)
  • to MTX or adalimumab
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Active comparator
    MTX

    Drug: Methotrexate (Metoject® prefilled pen)

  • Active comparator
    Adalimumab biosimilar

    Drug: Amgevita 40Mg Solution for Injection

Interventions

  • DrugAmgevita 40Mg Solution for Injection

    Amgevita 40mg

  • DrugMethotrexateStudies of MethotrexateMethotrexate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Metoject® PEN 7.5 mg, Metoject® PEN 10 mg, Metoject® PEN 15 mg, Metoject® PEN 20 mg, Metoject® PEN 25 mg

06

What researchers measure

Primary outcomes

  1. The change in erosion volume (mm³) in the MCPJ 2-4 over a period of 48 weeks between Group 1 (MTX) and Group 2 (TNFi group) assessed by HR-pQCT

    Time frame: 48 weeks

Secondary outcomes

  1. The change in erosion volume (mm³) in the MCPJ 2-4 over a period of 24 weeks

    Time frame: 24 weeks

  2. The proportion (in percentage) of erosions showing partial healing at weeks 24 and 48

    Time frame: Week 24 and 48

  3. The change in the enthesiophyte volume (mm³) at weeks 24 and 48

    Time frame: Weeks 24 and 48

  4. The proportion (in percentage) of enthesiophytes exhibiting progression at weeks 24 and 48

    Time frame: Week 24 and 48

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 33 phase 4 interventional studies under Arthritis, Psoriatic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 37. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Mar 23, 2026
StartActual
Mar 16, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07486843
Responsible party
Lai-Shan Tam (Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Mar 23, 2026
Start date
Mar 16, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Mar 23, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion